| Basics |
Repligen Corporation
Repligen Corp is a bioprocessing company developing, producing and commercializing biologic drugs. The company offers its products to life science companies, global biopharmaceutical companies, and contract manufacturers worldwide.
|
| IPO Date: |
March 26, 1990 |
| Sector: |
Healthcare |
| Industry: |
Life Sciences Tools and Services |
| Market Cap: |
$9.29B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$1.20 | 2.14%
|
| Avg Daily Range (30 D): |
$3.52 | 2.27%
|
| Avg Daily Range (90 D): |
$2.90 | 2.13%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.3M |
| Avg Daily Volume (30 D): |
.74M |
| Avg Daily Volume (90 D): |
.73M |
| Trade Size |
| Avg Trade Size (Sh.): |
70 |
| Avg Trade Size (Sh.) (30 D): |
43 |
| Avg Trade Size (Sh.) (90 D): |
43 |
| Institutional Trades |
| Total Inst.Trades: |
5,893 |
| Avg Inst. Trade: |
$5.05M |
| Avg Inst. Trade (30 D): |
$8.67M |
| Avg Inst. Trade (90 D): |
$8M |
| Avg Inst. Trade Volume: |
.05M |
| Avg Inst. Trades (Per Day): |
2 |
| Market Closing Trades |
| Avg Closing Trade: |
$7.27M |
| Avg Closing Trade (30 D): |
$16.47M |
| Avg Closing Trade (90 D): |
$15.62M |
| Avg Closing Volume: |
61.85K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
$.02
|
$.27
|
$.26
|
|
Diluted EPS
|
$.02
|
$.26
|
$.26
|
|
Revenue
|
$ 707.89M
|
$ 188.81M
|
$ 182.37M
|
|
Gross Profit
|
$ 321.26M
|
$ 100.52M
|
$ 91.14M
|
|
Net Income / Loss
|
$ 1.74M
|
$ 14.91M
|
$ 14.87M
|
|
Operating Income / Loss
|
$ .8M
|
$ 16.83M
|
$ 13.9M
|
|
Cost of Revenue
|
$ 386.64M
|
$ 88.29M
|
$ 91.22M
|
|
Net Cash Flow
|
$ -37.55M
|
$ 40.08M
|
$ 10.64M
|
|
PE Ratio
|
8,135.25
|
|
|
|
|
|
